{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:11:55Z","timestamp":1775815915151,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["QKHCG[2024]ZD012"],"award-info":[{"award-number":["QKHCG[2024]ZD012"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260036"],"award-info":[{"award-number":["82260036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360679"],"award-info":[{"award-number":["82360679"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060675"],"award-info":[{"award-number":["82060675"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["QKHPTRC-CXTD[2022]012"],"award-info":[{"award-number":["QKHPTRC-CXTD[2022]012"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmcl.2025.130429","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:54:19Z","timestamp":1759629259000},"page":"130429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and bio-evaluation of novel indolizine derivatives in FLT3 mutant acute myeloid leukemia cells"],"prefix":"10.1016","volume":"130","author":[{"given":"Qianlu","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangdong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjiao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130429_bb0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1024\/0040-5930\/a001126","article-title":"Diagnostik und therapie der akuten myeloischen leuk\u00e4mie","volume":"76","author":"Medinger","year":"2019","journal-title":"Ther Umsch"},{"key":"10.1016\/j.bmcl.2025.130429_bb0010","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2025.130429_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1159\/000531628","article-title":"Acute myeloid leukemia treatment in the elderly: a comprehensive review of the present and future","volume":"146","author":"Choi","year":"2023","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2021.280161","article-title":"The \u201c7+3\u201d regimen in acute myeloid leukemia","volume":"107","author":"Rowe","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2025.130429_bb0030","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","article-title":"Hematopoietic stem cell transplantation for acute myeloid leukemia","volume":"107","author":"Takami","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.hoc.2019.11.003","article-title":"Secondary acute myeloid leukemia: a primary challenge of diagnosis and treatment","volume":"34","author":"Winer","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.bmcl.2025.130429_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bjh.15077","article-title":"Treatment of relapsed\/refractory acute myeloid leukaemia in adults","volume":"181","author":"Rashidi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0045","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Option On"},{"key":"10.1016\/j.bmcl.2025.130429_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130429_bb0055","first-page":"325","article-title":"A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia","volume":"11","author":"Oliva","year":"2021","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.bmcl.2025.130429_bb0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.blre.2016.08.005","article-title":"Molecular biomarkers in acute myeloid leukemia","volume":"31","author":"Prada-Arismendy","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmcl.2025.130429_bb0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmcl.2025.130429_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11912-017-0573-x","article-title":"Treatment of acute myeloid leukemia with the FLT3 gene mutation","volume":"19","author":"Best-Aguilera","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.bmcl.2025.130429_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100928","article-title":"FLT3 mutational analysis in acute myeloid leukemia: advantages and pitfalls with different approaches","volume":"54","author":"Cumbo","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmcl.2025.130429_bb0085","article-title":"FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies","volume":"15","author":"Jalte","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.bmcl.2025.130429_bb0090","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2025.130429_bb0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3324\/haematol.2019.240754","article-title":"Potential targeting of FLT3 acute myeloid leukemia","volume":"106","author":"Ambinder","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2025.130429_bb0100","article-title":"Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia","author":"Lap","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.bmcl.2025.130429_bb0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1078155218802620","article-title":"FLT3 inhibitors in acute myeloid leukemia: current and future","volume":"25","author":"Thomas","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.bmcl.2025.130429_bb0115","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4155\/fmc-2019-0365","article-title":"Recent advances in FLT3 inhibitors for acute myeloid leukemia","volume":"12","author":"Tong","year":"2020","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130429_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13065-023-00981-8","article-title":"Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia","volume":"17","author":"Ezelarab","year":"2023","journal-title":"BMC Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0130","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3897\/folmed.63.e52891","article-title":"Regioselective synthesis of triazolo[3,4-e]purine derivatives and their anti-cancer activity against NCI-60 cell-lines","volume":"63","author":"Kapadiya","year":"2021","journal-title":"Folia Med"},{"key":"10.1016\/j.bmcl.2025.130429_bb0135","article-title":"Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: towards potential anticancer therapy","volume":"10","author":"Park","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bmcl.2025.130429_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122308","article-title":"Anticancer effect of covalent purine-containing EGFR TKI, ZZC4 and its mechanism of action through network pharmacology","volume":"336","author":"Attiogbe","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.bmcl.2025.130429_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105877","article-title":"Generation of a poly-functionalized indolizine scaffold and its anticancer activity in pancreatic cancer cells","volume":"126","author":"Lee","year":"2022","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108579","article-title":"Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets","volume":"254","author":"Mushtaq","year":"2024","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2025.130429_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216582","article-title":"Pyrrolizine\/indolizine-NSAID hybrids: design, synthesis, biological evaluation, and molecular docking studies","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2025.130429_bb0160","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.ejmech.2011.02.066","article-title":"Amberlite\u2013IRA-402 (OH) ion exchange resin mediated synthesis of indolizines, pyrrolo[1,2-a]quinolines and isoquinolines: antibacterial and antifungal evaluation of the products","volume":"46","author":"Hazra","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0165","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejps.2006.09.006","article-title":"Synthesis of indolizine derivatives with selective antibacterial activity against Mycobacterium tuberculosis","volume":"30","author":"Gundersen","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.bmcl.2025.130429_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217270","article-title":"Computational, crystallographic studies, cytotoxicity and anti-tubercular activity of substituted 7-methoxy-indolizine analogues","volume":"14","author":"Venugopala","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2025.130429_bb0175","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejmech.2017.12.056","article-title":"Biological evaluation of indolizine-chalcone hybrids as new anticancer agents","volume":"144","author":"Park","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/14756366.2018.1516651","article-title":"The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor","volume":"34","author":"Yu","year":"2019","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0185","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.bmcl.2015.07.025","article-title":"Discovery of indolizines containing triazine moiety as new leads for the development of antitumoral agents targeting mitotic events","volume":"25","author":"Lucescu","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2025.130429_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103371","article-title":"Ethyl benzoate bearing pyrrolizine\/indolizine moieties: Design, synthesis and biological evaluation of anti-inflammatory and cytotoxic activities","volume":"94","author":"Attalah","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0195","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.canlet.2016.07.030","article-title":"CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway","volume":"381","author":"Chen","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmcl.2025.130429_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104184","article-title":"Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity","volume":"103","author":"Moise","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0205","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/s41401-019-0237-5","article-title":"Y08197 is a novel and selective CBP\/EP300 bromodomain inhibitor for the treatment of prostate cancer","volume":"40","author":"Zou","year":"2019","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2025.130429_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101451","article-title":"New indazole-indolizine-triazine hybrid molecules with farnesyltransferase inhibitory activity","volume":"7","author":"Ciurl\u0103-Lucescu","year":"2024","journal-title":"Results Chem"},{"key":"10.1016\/j.bmcl.2025.130429_bb0215","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/13543776.2020.1798402","article-title":"Inhibitory activities of indolizine derivatives: a patent review","volume":"30","author":"Dawood","year":"2020","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2025.130429_bb0220","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1007\/s00044-014-0940-1","article-title":"Indolizine: a biologically active moiety","volume":"23","author":"Sharma","year":"2014","journal-title":"Med Chem Res"},{"key":"10.1016\/j.bmcl.2025.130429_bb0225","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1055\/a-2058-0119","article-title":"I2\/DTBP promoted synthesis of C3-carbonylated imidazopyridines from chromones and 2-aminopyridines via (3+2) cycloaddition","volume":"55","author":"Zhao","year":"2023","journal-title":"Synthesis"},{"key":"10.1016\/j.bmcl.2025.130429_bb0230","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.tetlet.2019.04.056","article-title":"Metal-free synthesis of novel indolizines from chromones and pyridinium salts via 1,3-dipolar cycloaddition, ring-opening and aromatization","volume":"60","author":"Dong","year":"2019","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2025.130429_bb0235","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","article-title":"Mitochondria as multifaceted regulators of cell death","volume":"21","author":"Bock","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130429_bb0240","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","article-title":"Mechanisms of Caspase activation and inhibition during apoptosis","volume":"9","author":"Shi","year":"2002","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmcl.2025.130429_bb0245","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.thromres.2022.11.024","article-title":"Platelet intrinsic apoptosis","volume":"231","author":"Josefsson","year":"2023","journal-title":"Thromb Res"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25003385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T08:15:19Z","timestamp":1761639319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25003385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0960894X25003385"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130429","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and bio-evaluation of novel indolizine derivatives in FLT3 mutant acute myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130429","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130429"}}